Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yasumasa Mitani, Alexander Lezhava, Aki Sakurai, Akina Horikawa, Makoto Nagakura, Yoshihide Hayashizaki & Toshihisa Ishikawa. (2009) Rapid and Cost-Effective SNP Detection Method: Application of SmartAmp2 to Pharmacogenomics Research. Pharmacogenomics 10:7, pages 1187-1197.
Read now
Read now
Jun Watanabe, Yasumasa Mitani, Yuki Kawai, Takeshi Kikuchi, Yasushi Kogo, Atsuko Oguchi-Katayama, Hajime Kanamori, Kengo Usui, Masayoshi Itoh, Paul E. Cizdziel, Alexander Lezhava, Kenji Tatsumi, Yasushi Ichikawa, Shinji Togo, Hiroshi Shimada & Yoshihide Hayashizaki. (2007) Use of a Competitive Probe in Assay Design for Genotyping of the UGT1A1*28 Microsatellite Polymorphism by the Smart Amplification Process. BioTechniques 43:4, pages 479-484.
Read now
Read now
Carmen Dumaual, Xin Miao, Thomas M Daly, Carsten Bruckner, Reuben Njau, Dong-Jing Fu, Sandra Close-Kirkwood, Nancy Bauer, Nancy Watanabe, Paul Hardenbol & Richard D Hockett. (2007) Comprehensive Assessment of Metabolic Enzyme and Transporter Genes Using the Affymetrix® Targeted Genotyping System. Pharmacogenomics 8:3, pages 293-305.
Read now
Read now
Rashmi R Shah. (2006) Can Pharmacogenetics Help Rescue Drugs Withdrawn from the Market?. Pharmacogenomics 7:6, pages 889-908.
Read now
Read now
Yoshinori Hasegawa, Yuichi Ando & Kaoru Shimokata. (2006) Screening for adverse reactions to irinotecan treatment using the Invader®UGT1A1 Molecular Assay. Expert Review of Molecular Diagnostics 6:4, pages 527-533.
Read now
Read now
Swati Nagar & Rebecca L. Blanchard. (2006) Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan. Drug Metabolism Reviews 38:3, pages 393-409.
Read now
Read now
Articles from other publishers (31)
Congjian Shi, Zhenghong Zhang, Renfeng Xu, Yan Zhang & Zhengchao Wang. (2023) Contribution of HIF-1α/BNIP3-mediated autophagy to lipid accumulation during irinotecan-induced liver injury. Scientific Reports 13:1.
Crossref
Crossref
Ruiming Zhang, Yi Luo, Chenghao Du, Ling Wu, Yankang Wang, Yuanduan Chen, Shouqian Li, Xin Jiang & Yongmei Xie. (2023) Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment. Bioorganic & Medicinal Chemistry Letters 81, pages 129128.
Crossref
Crossref
Yifan Tu, Lu Wang, Yi Rong, Vincent Tam, Taijun Yin, Song Gao, Rashim Singh & Ming Hu. (2021) Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. eLife 10.
Crossref
Crossref
Chalirmporn Atasilp, Phichai Chansriwong, Ekaphop Sirachainan, Thanyanan Reungwetwattana, Suwannee Sirilerttrakul, Monpat Chamnanphon, Apichaya Puangpetch & Chonlaphat Sukasem. (2020) Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific Reports 10:1.
Crossref
Crossref
Andrés López-Cortés, César Paz-y-Miño, Santiago Guerrero, Gabriela Jaramillo-Koupermann, Ángela León Cáceres, Dámaris P. Intriago-Baldeón, Jennyfer M. García-Cárdenas, Patricia Guevara-Ramírez, Isaac Armendáriz-Castillo, Paola E. Leone, Luis Abel Quiñones, Juan Pablo Cayún & Néstor W. Soria. (2019) Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. The Pharmacogenomics Journal 20:1, pages 136-158.
Crossref
Crossref
Sotaro Sadahiro, Toshiyuki Suzuki, Kazutake Okada, Gota Saito, Hiroshi Miyakita, Takashi Ogimi, Lin Fung Chan & Yutaro Kamei. (2020) Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. Oncology 98:9, pages 637-642.
Crossref
Crossref
Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou & Yong Tang. (2016) UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology 78:1, pages 119-130.
Crossref
Crossref
Kristina K. Wolf, Brandon T. Gufford, Scott J. Brantley, Paul B. Watkins & Mary F. Paine. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
626
638
.
Sotaro Sadahiro, Toshiyuki Suzuki, Akira Tanaka, Kazutake Okada, Gota Saito & Akemi Kamijo. (2015) A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology 88:6, pages 353-359.
Crossref
Crossref
May Garrett, Bill Poland, Meghan Brennan, Brian Hee, Yazdi K. Pithavala & Michael A. Amantea. (2014) Population pharmacokinetic analysis of axitinib in healthy volunteers. British Journal of Clinical Pharmacology 77:3, pages 480-492.
Crossref
Crossref
Mariusz Panczyk. (2014) Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World Journal of Gastroenterology 20:29, pages 9775.
Crossref
Crossref
Jun-ichi Yamakawa, Yoshiharu Motoo, Junji Moriya, Masao Ogawa, Hiroaki Uenishi, Sumiyo Akazawa, Toshiyuki Sasagawa, Matomo Nishio & Junji Kobayashi. (2013) Significance of Kampo, Traditional Japanese Medicine, in Supportive Care of Cancer Patients. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-10.
Crossref
Crossref
Jun-ichi Yamakawa, Yoshiharu Motoo, Junji Moriya, Masao Ogawa, Hiroaki Uenishi, Sumiyo Akazawa, Toshiyuki Sasagawa, Matomo Nishio & Junji Kobayashi. (2013) Role of Kampo Medicine in Integrative Cancer Therapy. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-6.
Crossref
Crossref
Toshihisa Ishikawa & Yoshihide Hayashizaki. 2013. Pharmacogenomics. Pharmacogenomics
55
69
.
Kouichi Kurose, Emiko Sugiyama & Yoshiro Saito. (2012) Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development. Drug Metabolism and Pharmacokinetics 27:1, pages 9-54.
Crossref
Crossref
Nobumitsu Hanioka, Natsuko Tanabe, Hideto Jinno, Toshiko Tanaka-Kagawa, Kenjiro Nagaoka, Shinsaku Naito, Akiko Koeda & Shizuo Narimatsu. (2010) Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sciences 87:7-8, pages 261-268.
Crossref
Crossref
Qiong Zhou, Zhijie Zheng, Bijun Xia, Lan Tang, Chang Lv, Wei Liu, Zhongqiu Liu & Ming Hu. (2010) Use of Isoform-Specific UGT Metabolism to Determine and Describe Rates and Profiles of Glucuronidation of Wogonin and Oroxylin A by Human Liver and Intestinal Microsomes. Pharmaceutical Research 27:8, pages 1568-1583.
Crossref
Crossref
Stephen W. J. Wang, Kaustubh H. Kulkarni, Lan Tang, Jing Rong Wang, Taijun Yin, Tomo Daidoji, Hiroshi Yokota & Ming Hu. (2009) Disposition of Flavonoids via Enteric Recycling: UDP-Glucuronosyltransferase (UGT) 1As Deficiency in Gunn Rats Is Compensated by Increases in UGT2Bs Activities. Journal of Pharmacology and Experimental Therapeutics 329:3, pages 1023-1031.
Crossref
Crossref
Patrick A. Thompson, Manish Gupta, Gary L. Rosner, Alexander Yu, Jeffrey Barrett, Lisa Bomgaars, Mark L. Bernstein, Susan M. Blaney & John Mondick. (2008) Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group. Cancer Chemotherapy and Pharmacology 62:6, pages 1027-1037.
Crossref
Crossref
John F. Deeken, Rebecca Slack & John L. Marshall. (2008) Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics. Cancer 113:7, pages 1502-1510.
Crossref
Crossref
Joanna Maudlin Pangilinan, Gazala N. Khan & Mark M. Zalupski. (2008) Irinotecan pharmacogenetics: an overview for the community oncologist. Community Oncology 5:2, pages 99-114.
Crossref
Crossref
Nick Orr & Stephen Chanock. 2008.
1
32
.
Tiby B. Joseph, Stephen W. J. Wang, Xing Liu, Kaustubh H. Kulkarni, Jingrong Wang, Haiyan Xu & Ming Hu. (2007) Disposition of Flavonoids via Enteric Recycling: Enzyme Stability Affects Characterization of Prunetin Glucuronidation across Species, Organs, and UGT Isoforms. Molecular Pharmaceutics 4:6, pages 883-894.
Crossref
Crossref
F. Ceppa, E. Fontan, S. Cremades, R. Bihannic, A. Bousquet, L. Beauvillain & P. Burnat. (2007) Implication de?la?pharmacog?n?tique dans?les?traitements des?cancers colorectaux. La Revue de M?decine Interne 28:9, pages 594-602.
Crossref
Crossref
Bernard Testa & Stefanie D. Krämer. (2007) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 4:9, pages 2031-2122.
Crossref
Crossref
Andrea L. Yoder Graber, Jacqueline Ramírez, Federico Innocenti & Mark J. Ratain. (2007) UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenetics and Genomics 17:8, pages 619-627.
Crossref
Crossref
Miki Nakajima, Sayaka Komagata, Yuto Fujiki, Yoshihiro Kanada, Hiromichi Ebi, Kuniaki Itoh, Hirofumi Mukai, Tsuyoshi Yokoi & Hironobu Minami. (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenetics and Genomics 17:6, pages 431-445.
Crossref
Crossref
Chih-Kang Huang, Alina Dulau, Chiao-Ju Su-Rick & Qiulu Pan. (2007) Validation of Rapid Polymerase Chain Reaction-based Detection of All Length Polymorphisms in the UGT 1A1 Gene Promoter. Diagnostic Molecular Pathology 16:1, pages 50-53.
Crossref
Crossref
Joanne M. Bowen, Rachel J. Gibson, Andrea M. Stringer, Thong W. Chan, Avanita S. Prabowo, Adrian G. Cummins & Dorothy M.K. Keefe. (2007) Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anti-Cancer Drugs 18:2, pages 197-210.
Crossref
Crossref
Joanne M. Bowen, Rachel J. Gibson, Adrian G. Cummins, Anna Tyskin & Dorothy M. K. Keefe. (2006) Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemotherapy and Pharmacology 59:3, pages 337-348.
Crossref
Crossref
Kazuhiro Araki, Ken‐ichi Fujita, Yuichi Ando, Fumio Nagashima, Wataru Yamamoto, Hisashi Endo, Toshimichi Miya, Keiji Kodama, Masaru Narabayashi & Yasutsuna Sasaki. (2006)
Pharmacogenetic impact of polymorphisms in the coding region of the
UGT1A1
gene on SN‐38 glucuronidation in Japanese patients with cancer
. Cancer Science 97:11, pages 1255-1259.
Crossref
Crossref